Skip to content

Author

Elisa N. Hofmeister

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era

It is argued that PROs should be incorporated as a primary or co-primary endpoint in most modern clinical trials, rather than as a point of interest in exploratory analyses, to better align clinical trial data with patient-centered treatment tolerability.

Elisa N. Hofmeister, A. Major · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.